Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Arbutus Biopharma Corporation ABUS

Set alert

Price alert · ABUS

All alert types
3.96 USD -0.04 -1.12%

As of Nov 3, 12:17 PM ET

Bid
3.95 × 2
Ask
3.96 × 2
3.88 Day range 4.06
3.50 52-week range 5.45
YTD
-17.78%
1 year
-13.65%
Open
4.01
Prev close
4.00
Mkt cap
606.21M
Vol
641.65K
Avg vol
4.92M
EPS
0.79
P/E
5.01
Div yield
0.00%
More statistics
Low
3.88
High
4.06
Forward P/E
-30.67
Beta
0.62
Short ratio
5.03
Inst. own
72.71%
Dividend
0.00
Ex-div date
Earnings
Nov 16, 2026
50-d avg
4.79
200-d avg
4.52
1y target
5.46

3M chart

Chart tools
Interval
1m5m15m30m

Events in this range
  • Aug 12, 2026Earnings: -0.03; estimate -0.02; surprise -50%
Signals (17)
NameDateAgo
MACD: Sell SignalNov 3, 20262 hours ago
RSI: OversoldNov 3, 20262 hours ago
MACD: Buy SignalOct 22, 20261 week ago
RSI: OversoldOct 12, 20263 weeks ago
RSI: OversoldOct 8, 20263 weeks ago
RSI: OversoldOct 2, 20261 month ago
SMA: BearishSep 29, 20261 month ago
MACD: Sell SignalSep 9, 20261 month ago
SMA: BullishAug 14, 20262 months ago
SMA: BearishAug 12, 20262 months ago
SMA: BullishAug 11, 20262 months ago
SMA: BearishAug 10, 20262 months ago
SMA: BullishAug 7, 20262 months ago
SMA: BearishAug 6, 20262 months ago
MACD: Buy SignalAug 6, 20262 months ago
SMA: BullishAug 5, 20263 months ago
SMA: BullishAug 5, 20263 months ago

Analyst view

Price target (mean) 5.46
Ratings (0m) 1 1 buy · 0 hold · 0 sell
  • Strong buy0
  • Buy1
  • Hold0
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 1
  • 1 month ago 1
  • 2 months ago 2

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

ABUS analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.028-0.028 – -0.028-0.05601+50.0%1.39M+87.4%1
Next quarter-0.028-0.028 – -0.028-0.01372-104.1%1.39M-3.7%1
Current year1.031.03 – 1.03-0.23321+540.4%252.84M+1208.8%1
Next year-0.111-0.111 – -0.1111.03-110.8%5.69M-97.8%1

Upgrades and downgrades

The latest rating changes

ABUS analyst upgrades and downgrades
DateFirmActionFromTo
Nov 14, 2025Chardan CapitalMaintainedBuyBuy
Aug 11, 2025Chardan CapitalMaintainedBuyBuy
Mar 28, 2025Chardan CapitalMaintainedBuyBuy
Jan 21, 2025HC Wainwright & Co.ReiteratedBuyBuy
Nov 20, 2024Chardan CapitalMaintainedBuyBuy
Nov 18, 2024HC Wainwright & Co.ReiteratedBuyBuy
Nov 7, 2024HC Wainwright & Co.ReiteratedBuyBuy
Nov 6, 2024Chardan CapitalMaintainedBuyBuy
Sep 5, 2024JefferiesMaintainedBuyBuy
Aug 2, 2024JMP SecuritiesMaintainedMarket OutperformMarket Outperform
Jun 7, 2024HC Wainwright & Co.ReiteratedBuyBuy
Jun 6, 2024HC Wainwright & Co.ReiteratedBuyBuy
Jun 5, 2024Chardan CapitalMaintainedBuyBuy
May 3, 2024Chardan CapitalReiteratedBuyBuy
Apr 4, 2024JMP SecuritiesReiteratedMarket OutperformMarket Outperform
Mar 1, 2024Chardan CapitalReiteratedBuyBuy
Mar 1, 2024HC Wainwright & Co.MaintainedBuyBuy
Sep 12, 2023HC Wainwright & Co.ReiteratedBuyBuy
Aug 4, 2023HC Wainwright & Co.ReiteratedBuyBuy
Aug 4, 2023Chardan CapitalReiteratedBuyBuy
Jul 11, 2023HC Wainwright & Co.ReiteratedBuyBuy
Jul 6, 2023JMP SecuritiesReiteratedMarket OutperformMarket Outperform
Jun 22, 2023HC Wainwright & Co.ReiteratedBuyBuy
Jun 22, 2023Chardan CapitalReiteratedBuyBuy
May 5, 2023HC Wainwright & Co.Reiterated—Buy
Apr 28, 2023HC Wainwright & Co.Reiterated—Buy
Apr 5, 2023HC Wainwright & Co.Reiterated—Buy
Mar 29, 2023JMP SecuritiesReiterated—Market Outperform
Mar 20, 2023HC Wainwright & Co.Reiterated—Buy
Mar 3, 2023Chardan CapitalReiterated—Buy